IOncology

CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021 American Association for Cancer Research (AACR) meeting. The findings demonstrated even greater benefits in Chinese patients compared to the global population, generating significant academic interest and establishing first-line immunotherapy plus chemotherapy as the standard of care for advanced gastric cancer in China. Today, nivolumab in combination with chemotherapy has been approved as a first-line treatment for advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) in more than 50 countries, including the United States and China.

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.

Editor's Note: With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of…

Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor Abdel Ghani Atef from the Damas Liver & G.I.T Center in Egypt presented research on the value of ultrasound elastography in the early detection of HCC in patients with cirrhosis. To this end, a journalist from Oncology Frontier traveled to the summit and invited Professor Abdel Ghani Atef to have an in-depth discussion on topics such as the role of FibroScan in HCC screening and the significance of liver stiffness measurement cutoff values.

A recent study published in JNCI Cancer Spectrum (Jan 2025) introduces a machine learning-based cancer-specific cardiovascular disease (CVD) risk score, designed to improve risk prediction for breast, colorectal, and lung…

A newly published study in ESMO Open (Jan 2025) led by H. S. Rugo, R. M. Layman, F. Lynce, G. Curigliano, A. Brufsky, and colleagues analyzed real-world overall survival (OS)…